Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
Nvidia Nears $30 Billion Investment in OpenAI, Replacing Previous $100 Billion AI Partnership 
HSBC Cuts 10% of U.S. Debt Capital Markets Team Amid Ongoing Business Revamp 
Meta Platforms Cuts Equity Awards Again Amid Massive AI Investment Push 
OpenAI Targets $600B Compute Spend as IPO Valuation Could Reach $1 Trillion 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Alibaba, Baidu, BYD Shares Slide After Pentagon Military List Update 
FERC Approves Blackstone Infrastructure’s Acquisition of TXNM Energy, Advancing Utility Merger 
PacifiCorp to Pay $575 Million in Wildfire Settlement With U.S. Government 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
LAWRENCEVILLE, N.J., May 08, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held on May 8 – 9, 2018 at Reed Smith, LLP in New York City. Mr. Tardugno’s presentation details are as follows:
Corporate Presentation:
- Date and Time: Tuesday, May 8, 2017 at 9:30 a.m. – 9:50 a.m. EDT
- Location: Room A/B
Slide Presentation Available on Celsion’s Website
To view Mr. Tardugno’s slide presentation from the event, please visit Celsion’s corporate website at http://investor.celsion.com/financial-events .
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
